Skip to main content

Displaying 121 - 140 of 1406

Jul27

PrivacyCon 2021

The FTC hosted its sixth annual PrivacyCon on July 27, 2021. PrivacyCon 2021 brought together a diverse group of stakeholders, including researchers, academics, industry representatives, consumer...

ZyCal Bioceuticals Healthcare Company, Inc.

In February 2020, the FTC filed a complaint in federal district court against ZyCal Bioceuticals, a company that manufactured and sold the ingredient Cyplexinol to trade customers for use in making pain relief products for joint ailments, such as arthritis. Zycal also marketed a line of Cyplexinol-based pain relief products to chiropractors and directly to consumers under the brand name Ostinol. The same complaint includes allegations against another company, Excellent Marketing Results, Inc. (EMR), which was one of ZyCal's trade customers. EMR marketed a Cyplexinol-based formulation called StimTein via infomercials and online, and claimed it was clinically proven to stimulate cells to grow bone tissue and cartilage. EMR and its president agreed to a settlement that resolves charges against them in the FTC’s complaint, and prohibits them from making such health-related product claims unless they are supported by competent and reliable scientific evidence. In September 2020, the FTC announced it was returning more than $110,000 to consumers who bought EMR’s StimTein.

Type of Action
Federal
Last Updated
FTC Matter/File Number
182 3133
Case Status
Pending